Improve Human Health to Preserve Patients’ Dignity

Leading the advancement of innovative therapies in genitourinary tumors and women's health

Highlights

Asieris and SPH Kyuan Trade Announce Import and Distribution Strategic Partnership to Accelerate the Commercialization of Cevira®

Products

Vesique^®(APL-1202) | Cevira^® (APL-1702)

Core Areas

Urologic Oncology

Integrated diagnosis and treatment, reinforced by strengthened leadership

Women's Health

Building a robust and tiered gynecology pipeline with game-changing products

Breast and Gynecologic Oncology

Synergizing in-house R&D and licensing to cover both early- and late-stage needs

Global Partnership

News & Updates

Asieris and SPH Kyuan Trade Announce Import and Distribution Strategic Partnership to Accelerate the Commercialization of Cevira®

Asieris’ CEVIRA® Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

February 27, 2026

Asieris Announces European Medicines Agency Accepts Marketing Authorization Application for APL-1702

January 22, 2026

Asieris Receives Approval in Australia for Phase I Study of APL-2401 in Patients with FGFR2/3-Driven Advanced Solid Tumors

January 8, 2026

Asieris Enrolls First Patient in China in Phase I Clinical Trial of APL-2401 for Patients with FGFR2/3-Driven Advanced Solid Tumors

January 7, 2026

Asieris Pharmaceuticals Appoints Dr. Ningshu Liu as Chief Scientific Officer

Technology Platform